© 2020 MJH Life Sciences and Cure Today. All rights reserved.
© 2020 MJH Life Sciences™ and Cure Today. All rights reserved.
July 13th 2020, 7:00pm
“Having new options is important, particularly when patients have already been through chemotherapy and some of the other therapies that are available,” said Dr. John P. Leonard.
June 18th 2020, 10:26pm
The Food and Drug Administration approved Tazverik for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and have received treatment with at least two systemic therapies, as well as patients who have no other treatment options.